

OncoTherapy Science, Inc.

July 29, 2016

The expiration of license agreement signed by OncoTherapy  
for compact automatic emulsion-preparing device

OncoTherapy Science, Inc. (hereinafter, “OncoTherapy”) announces that the license agreement (hereinafter “Agreement”) executed on July 29, 2013 between OncoTherapy and SEPPIC (Société d'Exploitation de Produits pour les Industries Chimiques) S.A. (hereinafter, “SEPPIC”: HQ in Paris.), which markets specialty ingredients for health and beauty care in more than 100 countries, has expired today.

Under this Agreement, OncoTherapy granted SEPPIC the world-wide exclusive rights to manufacture and sell the compact automatic emulsion-preparing device, for which OncoTherapy possesses IP rights. The Agreement matured full term.

In cancer immunotherapy field OncoTherapy promotes peptide vaccine business, vaccine therapy utilizing dendritic cell therapy and TCR analysis business, and at the same time regards it as one of important factors to bring up relevant technology that contributes to cancer immunotherapy. We will continue to effectively utilize the compact automatic emulsion-preparing device as a part of such relevant technologies.

< Compact Automatic Emulsion-Preparing Device >

Compact Automatic Emulsion-Preparing Device is a device for preparation of emulsion by automatically agitating peptide solution and an adjuvant\* in syringes. This device is useful for the relief in preparation work of emulsion in hospitals as compared to conventional manual preparation and the standardization of emulsion.

\*Adjuvant: a pharmacological agent that is administered with an antigen (e.g., peptide) for increasing immunogenicity of the antigen.